Bactericidal Activity of Pradofloxacin and Other Antimicrobials Against Swine Respiratory Bacterial Pathogens.

Abstract read

In one paragraph

Article in Pathogens (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

A Review of Fluoroquinolones with a Focus on Veterinary-Approved Agents.Biomolecules · 2026
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Joseph M BlondeauDepartment of Clinical Microbiology, Royal University Hospital and Saskatchewan Health Authority, Saskatoon, SK S7N 0W8, Canada.ORCID 0000-0003-3396-0334

Shantelle D FitchDepartment of Clinical Microbiology, Royal University Hospital and Saskatchewan Health Authority, Saskatoon, SK S7N 0W8, Canada.

Funding

Elanco (United States) #205235 10300

6 · The paper itself

Abstract

Swine respiratory disease (SRD) is a complex interaction whereby viral infection predisposes the host to secondary bacterial pulmonary invasion, which may be fatal. Antimicrobial agents remain an important therapy and serve to reduce morbidity and mortality in treated animals. Pradofloxacin is the newest of the veterinary antibiotics to be approved to treat SRD. It is a dual-targeting fluoroquinolone with in vitro and clinical activity against Gram-negative and -positive bacteria, along with atypical agents including anaerobes. In this study, we compared the killing of

Indexed as

Actinobacillus pleuropneumoniaeAnti-Bacterial AgentsFluoroquinolonesMicrobial ViabilityPasteurella multocidaRespiratory Tract InfectionsStreptococcus suisSwine DiseasesAnimalsMicrobial Sensitivity TestsSwineAnti-Bacterial AgentsFluoroquinolonespradofloxacinbacterial infectionpradofloxacinswine

Identifiers

PMID41305407

DOI10.3390/pathogens14111171

PMCPMC12655739

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.